196 related articles for article (PubMed ID: 10646902)
21. Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity.
Kumpel BM; Rademacher TW; Rook GA; Williams PJ; Wilson IB
Hum Antibodies Hybridomas; 1994; 5(3-4):143-51. PubMed ID: 7756579
[TBL] [Abstract][Full Text] [Related]
22. A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis.
Wijngaarden S; van de Winkel JG; Jacobs KM; Bijlsma JW; Lafeber FP; van Roon JA
Arthritis Rheum; 2004 Dec; 50(12):3878-87. PubMed ID: 15593228
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
24. Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2.
Flieger D; Spengler U; Beier I; Sauerbruch T; Schmidt-Wolf I
Cytokine; 2000 Jun; 12(6):756-61. PubMed ID: 10843759
[TBL] [Abstract][Full Text] [Related]
25. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering.
Schuster M; Umana P; Ferrara C; Brünker P; Gerdes C; Waxenecker G; Wiederkum S; Schwager C; Loibner H; Himmler G; Mudde GC
Cancer Res; 2005 Sep; 65(17):7934-41. PubMed ID: 16140965
[TBL] [Abstract][Full Text] [Related]
26. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
27. Defective mononuclear cell antibody-dependent cellular cytotoxicity (ADCC) in patients with leukocyte adhesion deficiency emphasizing on different CD11/CD18 requirement of Fc gamma RI versus Fc gamma RII in ADCC.
Majima T; Ohashi Y; Nagatomi R; Iizuka A; Konno T
Cell Immunol; 1993 May; 148(2):385-96. PubMed ID: 8098672
[TBL] [Abstract][Full Text] [Related]
28. Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity.
Nagashima H; Tezuka T; Tsuchida W; Maeda H; Kohroki J; Masuho Y
Mol Immunol; 2008 May; 45(10):2752-63. PubMed ID: 18353438
[TBL] [Abstract][Full Text] [Related]
29. Soluble tumour necrosis factor receptor release after anti-CD3 monoclonal antibody treatment in mice is independent of tumour necrosis factor-alpha release.
Vossen AC; Tibbe GJ; Buurman WA; Benner R; Savelkoul HF
Eur Cytokine Netw; 1996 Dec; 7(4):751-5. PubMed ID: 9010677
[TBL] [Abstract][Full Text] [Related]
30. FcgammaR: The key to optimize therapeutic antibodies?
Sibéril S; Dutertre CA; Fridman WH; Teillaud JL
Crit Rev Oncol Hematol; 2007 Apr; 62(1):26-33. PubMed ID: 17240158
[TBL] [Abstract][Full Text] [Related]
31. Addition of an extra immunoglobulin domain to two anti-rodent TNF monoclonal antibodies substantially increased their potency.
Scallon B; Cai A; Radewonuk J; Naso M
Mol Immunol; 2004 May; 41(1):73-80. PubMed ID: 15140577
[TBL] [Abstract][Full Text] [Related]
32. Cytolytic interactions between murine macrophages, tumor cells, and monoclonal antibodies: characterization of lytic conditions and requirements for effector activation.
Johnson WJ; Steplewski Z; Matthews TJ; Hamilton TA; Koprowski H; Adams DO
J Immunol; 1986 Jun; 136(12):4704-13. PubMed ID: 3711663
[TBL] [Abstract][Full Text] [Related]
33. A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies.
Beliard R; Waegemans T; Notelet D; Massad L; Dhainaut F; Romeuf Cd; Guemas E; Haazen W; Bourel D; Teillaud JL; Prost JF
Br J Haematol; 2008 Apr; 141(1):109-19. PubMed ID: 18279459
[TBL] [Abstract][Full Text] [Related]
34. Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys.
Co MS; Baker J; Bednarik K; Janzek E; Neruda W; Mayer P; Plot R; Stumper B; Vasquez M; Queen C; Loibner H
Cancer Res; 1996 Mar; 56(5):1118-25. PubMed ID: 8640770
[TBL] [Abstract][Full Text] [Related]
35. Role of Fc gamma receptors in triggering host cell activation and cytokine release by Borrelia burgdorferi.
Talkington J; Nickell SP
Infect Immun; 2001 Jan; 69(1):413-9. PubMed ID: 11119532
[TBL] [Abstract][Full Text] [Related]
36. The influence of antibody sensitization on target cell selection in monocyte-mediated antibody-dependent cellular cytotoxicity.
Bakács T; Ringwald G; Léránth T; Kimber I
J Clin Lab Immunol; 1988 Oct; 27(2):57-62. PubMed ID: 3246684
[TBL] [Abstract][Full Text] [Related]
37. Cytokine-mediated regulation of activating and inhibitory Fc gamma receptors in human monocytes.
Liu Y; Masuda E; Blank MC; Kirou KA; Gao X; Park MS; Pricop L
J Leukoc Biol; 2005 May; 77(5):767-76. PubMed ID: 15703199
[TBL] [Abstract][Full Text] [Related]
38. Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions.
Sibéril S; de Romeuf C; Bihoreau N; Fernandez N; Meterreau JL; Regenman A; Nony E; Gaucher C; Glacet A; Jorieux S; Klein P; Hogarth MP; Fridman WH; Bourel D; Béliard R; Teillaud JL
Clin Immunol; 2006; 118(2-3):170-9. PubMed ID: 16332457
[TBL] [Abstract][Full Text] [Related]
39. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M
Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of norepinephrine-mediated inhibition of human NK cytotoxic functions: inhibition of cytokine secretion, target binding, and programming for cytotoxicity.
Gan X; Zhang L; Solomon GF; Bonavida B
Brain Behav Immun; 2002 Jun; 16(3):227-46. PubMed ID: 12009684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
